- Home
- ELEV vs ADVB Comparison
ELEV vs ADVB Comparison
Compare ELEV & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- ADVB
- Stock Information
- Founded
- ELEV 2019
- ADVB 2014
- Country
- ELEV United States
- ADVB United States
- Employees
- ELEV N/A
- ADVB N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- ELEV Health Care
- ADVB Health Care
- Exchange
- ELEV Nasdaq
- ADVB Nasdaq
- Market Cap
- ELEV 22.6M
- ADVB 20.8M
- IPO Year
- ELEV 2021
- ADVB 2025
- Fundamental
- Price
- ELEV $0.38
- ADVB $0.76
- Analyst Decision
- ELEV Hold
- ADVB
- Analyst Count
- ELEV 6
- ADVB 0
- Target Price
- ELEV $1.77
- ADVB N/A
- AVG Volume (30 Days)
- ELEV 938.5K
- ADVB 164.4K
- Earning Date
- ELEV 08-05-2025
- ADVB 08-03-2025
- Dividend Yield
- ELEV N/A
- ADVB N/A
- EPS Growth
- ELEV N/A
- ADVB N/A
- EPS
- ELEV N/A
- ADVB N/A
- Revenue
- ELEV N/A
- ADVB N/A
- Revenue This Year
- ELEV N/A
- ADVB N/A
- Revenue Next Year
- ELEV N/A
- ADVB N/A
- P/E Ratio
- ELEV N/A
- ADVB N/A
- Revenue Growth
- ELEV N/A
- ADVB N/A
- 52 Week Low
- ELEV $0.22
- ADVB $0.56
- 52 Week High
- ELEV $3.28
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- ELEV 54.73
- ADVB N/A
- Support Level
- ELEV $0.36
- ADVB N/A
- Resistance Level
- ELEV $0.38
- ADVB N/A
- Average True Range (ATR)
- ELEV 0.01
- ADVB 0.00
- MACD
- ELEV -0.00
- ADVB 0.00
- Stochastic Oscillator
- ELEV 53.93
- ADVB 0.00
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.